Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 1,307 trials

Multiple Sclerosis: Frexalimab vs. Teriflunomide

We are studying a new medication, frexalimab, for adults with relapsing forms of multiple sclerosis. The goal is to see if it works better than teriflunomide in reducing relapses and improving quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Frexalimab for Nonrelapsing Secondary Progressive Multiple Sclerosis

We are studying whether frexalimab can help delay disability progression in adults with nonrelapsing secondary progressive multiple sclerosis. The trial also examines its effects on quality of life and safety.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cervical Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for women and young adults with high-risk locally advanced cervical cancer after initial treatment. This trial compares volrustomig to a placebo to see if it improves health outcomes.

Locally Advanced Cervical CancerConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteOncology

Chronic Hepatitis D: Bulevirtide Treatment Study

We are studying the effects of Bulevirtide in patients with chronic hepatitis D to see how well it reduces the virus and improves liver health. This research will help us understand the treatment's safety and effectiveness over time.

Hepatitis DConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Atopic Dermatitis: Methotrexate Injection Study

We are testing whether subcutaneous methotrexate can improve skin symptoms in adults with moderate to severe atopic dermatitis compared to a placebo. The study also examines safety and quality of life for participants.

Moderate to Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesAllergologyDermatology

Fibrotic Lung Disease: Inhaled Treprostinil Study

We are evaluating the long-term safety of inhaled treprostinil for individuals with fibrotic lung diseases. This study is for those who have previously participated in related trials and need ongoing treatment.

Lung Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Head and Neck Cancer: Pembrolizumab with Radiotherapy

We are studying if adding radiotherapy to pembrolizumab helps patients with limited spread of head and neck cancer live longer and feel better. This trial focuses on those with a specific type of cancer and aims to compare treatment effects and safety.

Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Rosuvastatin for Preventing Venous Thromboembolism Recurrence

We are studying whether generic rosuvastatin can help prevent further blood clots in patients with a history of venous thromboembolism. We will also look at its safety and effects on bleeding and other vascular events.

Deep Vein ThrombosisPulmonary EmbolismVenous Thromboembolism>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyHematology

Cardiac Surgery: DOAC vs. Vitamin K Antagonist Study

We are studying the safety of two blood thinners for patients with atrial fibrillation after heart surgery. This research may help determine the best anticoagulation treatment for these patients.

Atrial Fibrillation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Aortic Stenosis: Protamine for Heart Procedure Safety

We are studying whether using protamine sulfate can reduce complications like strokes and bleeding during heart valve surgery. This trial is for patients with aortic stenosis undergoing transcatheter aortic valve implantation.

Cardiovascular Disorder>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Duchenne Muscular Dystrophy: GIVINOSTAT Study

We are evaluating the long-term safety and effects of GIVINOSTAT in patients with Duchenne Muscular Dystrophy who have previously been treated with this drug. The study aims to understand its impact on muscle strength, respiratory function, and daily life.

Duchenne Muscular Dystrophy3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

aHUS: Switching to Iptacopan Treatment

We are studying whether switching from anti-C5 antibody therapy to iptacopan can help people with aHUS avoid complications. The trial will also assess the safety and effects on blood and kidney health.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyNephrology

Papulopustular Acne: Clindamycin/Tretinoin Gel Study

We are evaluating a new gel with Clindamycin and Tretinoin for treating papulopustular acne. The study compares its effects to an existing treatment and a placebo to see which works best.

Papulopustular Acne≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatology

Large Incisional Hernia: Botulinum Toxin A Injection Study

We are investigating whether injecting botulinum toxin A before surgery helps reduce complications and improve recovery for patients with large incisional hernias. This study compares the effects of BTA to a placebo injection.

Incisional Hernia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementGastroenterologyOrthopedics and Traumatology

GVHD Prevention in Elderly AML/MDS Patients: Thymoglobulin vs. Grafalon

We are comparing two treatments to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome receiving stem cell transplants. The goal is to find out which treatment leads to better outcomes after transplantation.

Acute Myeloid LeukemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Trigeminal Neuralgia: Botox Treatment Study

We are exploring whether Botox can effectively reduce pain in patients with trigeminal neuralgia compared to a placebo. Additionally, we’re investigating if specific biomarkers can help predict treatment response.

Trigeminal Neuralgia3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Hypotension Treatment: Early Vasopressor Therapy

We are studying whether starting vasopressor therapy early helps hypotensive patients in the emergency department recover faster than standard fluid therapy. This may reduce the need for intensive care admission.

Low Blood Pressure (Hypotension)Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious DiseasesInternal MedicinePulmonology

Focal Segmental Glomerulosclerosis: DMX-200 Treatment Study

We are studying the effects of DMX-200 on kidney function in patients with focal segmental glomerulosclerosis who are taking an angiotensin II receptor blocker. This trial will help us understand its safety and effectiveness compared to standard treatments.

Focal Segmental Glomerulosclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrology

Hepatocellular Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a combination of two medications for people with advanced liver cancer who have not had prior treatment. The goal is to find the best dose and assess safety and effectiveness.

Metastatic Liver Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Alzheimer's Disease: Rotigotine and Rivastigmine Study

We are testing a combination of rotigotine and rivastigmine to see if it improves thinking skills and daily activities in people with mild to moderate Alzheimer's disease. This study compares the new treatment to rivastigmine with a placebo.

Mild to Moderate Alzheimer's Disease3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteNeurology